A Study to Compare the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab® in NSCLC
Status:
Recruiting
Trial end date:
2021-11-10
Target enrollment:
Participant gender:
Summary
This is a double-blind Phase 3 clinical trial evaluating the efficacy and safety of TRS003
and paclitaxel-carboplatin versus China-approved bevacizumab and paclitaxel-carboplatin in
patients with unresectable, locally advanced, or metastatic non-squamous non-small cell lung
cancer (NSCLC). Approximately 608 patients will be enrolled in this study from America,
Europe, and Asia. Patients who sign the informed consent and meet the inclusion criteria,
will be randomized (1:1) to receive either TRS003 in combination with paclitaxel and
carboplatin or China-approved bevacizumab in combination with paclitaxel and carboplatin for
4 to 6 cycles.